NantHealth Ranked Number 304 Fastest Growing Company in North America on Deloitte’s 2017 Technology Fast 500™
November 15 2017 - 7:00AM
Business Wire
Company attributes 276 percent revenue growth
in 2017 to GPS Cancer™ and advanced oncology solutions
NantHealth, Inc. (NASDAQ-GS: NH), a next-generation,
evidence-based, personalized healthcare company, announced today a
ranking of 304 on Deloitte’s Technology Fast 500™, a ranking of the
500 fastest growing technology, media, telecommunications, life
sciences and energy tech companies in North America.
NantHealth’s founder and chief executive officer, Patrick
Soon-Shiong, MD, credits GPS Cancer™ adoption, the company’s
ability to offer the latest software technology that supports
advancements in precision medicine and the company’s 276 percent
revenue growth for the significant accomplishment. Dr. Soon-Shiong
said, "Over the years we’ve seen significant adoption of technology
solutions to advance healthcare, and for NantHealth to be a top
contender in the health technology space is a testament to GPS
Cancer and our best-in-class oncology solutions. We’re looking
forward to our committed journey toward achieving precision
medicine and we are honored to be recognized by Deloitte."
“The Deloitte 2017 North America Technology Fast 500 winners
underscore the impact of technological innovation and world class
customer service in driving growth, in a fiercely competitive
environment,” said Sandra Shirai, vice chairman, Deloitte
Consulting LLP and U.S. technology, media and telecommunications
leader. “These companies are on the cutting edge and are
transforming the way we do business. We extend our sincere
congratulations to all the winners for achieving remarkable growth
while delivering new services and experiences for their
customers.”
“Emerging growth companies are powering innovation in the
broader economy. The growth rates delivered by the companies on
this year’s North America Technology Fast 500 ranking are a bright
spot for the capital markets and a strong indicator that the
emerging growth technology sector will continue to deliver a strong
return on investment,” said Heather Gates, national managing
director of Deloitte & Touche LLP’s emerging growth company
practice. “Deloitte is dedicated to supporting the best and
brightest companies of the future in the emerging growth company
sector. We are proud to acknowledge the significant accomplishments
of this year’s Fast 500 winners.”
About Deloitte’s 2017 Technology Fast 500™
Deloitte’s Technology Fast 500 provides a ranking of the fastest
growing technology, media, telecommunications, life sciences and
energy tech companies — both public and private — in North America.
Technology Fast 500 award winners are selected based on percentage
fiscal year revenue growth from 2013 to 2016.
In order to be eligible for Technology Fast 500 recognition,
companies must own proprietary intellectual property or technology
that is sold to customers in products that contribute to a majority
of the company’s operating revenues. Companies must have base-year
operating revenues of at least $50,000 USD, and current-year
operating revenues of at least $5 million USD. Additionally,
companies must be in business for a minimum of four years and be
headquartered within North America.
Deloitte refers to one or more of Deloitte Touche Tohmatsu
Limited, a UK private company limited by guarantee (“DTTL”), its
network of member firms, and their related entities. DTTL and each
of its member firms are legally separate and independent entities.
DTTL (also referred to as “Deloitte Global”) does not provide
services to clients. In the United States, Deloitte refers to one
or more of the US member firms of DTTL, their related entities that
operate using the “Deloitte” name in the United States and their
respective affiliates. Certain services may not be available to
attest clients under the rules and regulations of public
accounting. Please see www.deloitte.com/about to learn more
about our global network of member firms.
Cautionary Note Concerning Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including, among others, statements regarding the
capabilities and anticipated utility of our GPS Cancer, including
predicting patient response and resistance to therapeutics,
enabling diagnoses by physicians and accelerating efforts to bring
novel combinations of therapeutic agents to cancer patients.
Forward-looking statements are subject to numerous risks and
uncertainties that could cause actual results to differ materially
from currently anticipated results. Factors that may cause future
results to differ materially from management’s current expectations
include, among other things, that GPS Cancer may not perform as
anticipated, that sufficient physicians may not adopt GPS Cancer to
assist their diagnoses or that healthcare payers may not provide
reimbursement for GPS Cancer as expected. Our business is subject
to numerous additional risks and uncertainties, including, among
others, risks relating to market acceptance of our products; our
ability to successfully launch new products and applications;
competition; our sales, marketing and distribution capabilities;
our planned sales, marketing, and research and development
activities; unanticipated increases in costs or expenses; and risks
associated with international operations. Information on these and
additional risks, uncertainties, and other information affecting
our business and operating results can be found in our existing and
future filings with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date hereof. We
disclaim any obligation to update these forward-looking statements
except as may be required by law.
About NantHealth, Inc.
NantHealth, Inc., a member of the NantWorks ecosystem of
companies, is a next-generation, evidence-based, personalized
healthcare company enabling improved patient outcomes and more
effective treatment decisions for critical illnesses. NantHealth’s
unique systems-based approach to personalized healthcare applies
novel diagnostics tailored to the specific molecular profiles of
patient tissues and integrates this molecular data in a clinical
setting with large-scale, real-time biometric signal and phenotypic
data to track patient outcomes and deliver precision medicine. For
nearly a decade, NantHealth has developed an adaptive learning
system, which includes its unique software, middleware and hardware
systems infrastructure that collects, indexes, analyzes and
interprets billions of molecular, clinical, operational and
financial data points derived from novel and traditional sources,
continuously improves decision-making and further optimizes our
clinical pathways and decision algorithms over time. For more
information please visit www.nanthealth.com and follow
Dr. Soon-Shiong on Twitter @DrPatSoonShiong.
About GPS Cancer™
GPS Cancer™ is a unique, molecular scan available through
NantHealth. GPS Cancer integrates whole genome (DNA) sequencing,
whole transcriptome (RNA) sequencing, and quantitative proteomics
through mass spectrometry, providing oncologists with a
comprehensive molecular profile of a patient’s cancer and an
assessment of protein pathway function to inform personalized
treatment strategies. GPS Cancer scanning is conducted in
CLIA-certified and CAP-accredited laboratories, and is a key
enabler for Cancer Breakthroughs 2020, the world’s most
comprehensive cancer collaborative initiative seeking to accelerate
the potential of combination immunotherapy as the next generation
standard of care in cancer patients. For more information,
visit www.gpscancer.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171115005473/en/
NantWorksJen Hodsonjhodson@nantworks.com
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Apr 2024 to May 2024
NantHealth (NASDAQ:NH)
Historical Stock Chart
From May 2023 to May 2024